مصطلحات الفهرس: case report, clinical article, creatinine blood level, disease activity, drug substitution, drug withdrawal, end stage renal disease/su [Surgery], female, graft infection/co [Complication], graft infection/dt [Drug Therapy], graft recipient, graft versus host reaction/pc [Prevention], human, human tissue, kidney biopsy, kidney graft rejection/dt [Drug Therapy], kidney transplantation, leukopenia, lymphocytopenia, microsporidiosis/co [Complication], microsporidiosis/dt [Drug Therapy], middle aged, neutropenia, plasma exchange, priority journal, renal graft dysfunction, rheumatoid arthritis/dt [Drug Therapy], vestibular neuronitis, albendazole/dt [Drug Therapy], tacrolimus/cb [Drug Combination], tacrolimus/dt [Drug Therapy], graft versus host reaction/dt [Drug Therapy], albendazole/po [Oral Drug Administration], basiliximab/cb [Drug Combination], basiliximab/dt [Drug Therapy], creatinine/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], methotrexate/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], pantoprazole, prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], ranitidine, salazosulfapyridine/dt [Drug Therapy], adult, article, bone marrow transplantation, Article

URL: Transplant Infectious Disease
Click here for full text options
LibKey Link

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602Test
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

مصطلحات الفهرس: case report, clinical article, creatinine blood level, disease activity, drug substitution, drug withdrawal, end stage renal disease/su [Surgery], female, graft infection/co [Complication], graft infection/dt [Drug Therapy], graft recipient, graft versus host reaction/pc [Prevention], human, human tissue, kidney biopsy, kidney graft rejection/dt [Drug Therapy], kidney transplantation, leukopenia, lymphocytopenia, microsporidiosis/co [Complication], microsporidiosis/dt [Drug Therapy], middle aged, neutropenia, plasma exchange, priority journal, renal graft dysfunction, rheumatoid arthritis/dt [Drug Therapy], vestibular neuronitis, albendazole/dt [Drug Therapy], tacrolimus/cb [Drug Combination], tacrolimus/dt [Drug Therapy], graft versus host reaction/dt [Drug Therapy], albendazole/po [Oral Drug Administration], basiliximab/cb [Drug Combination], basiliximab/dt [Drug Therapy], creatinine/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], methotrexate/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], pantoprazole, prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], ranitidine, salazosulfapyridine/dt [Drug Therapy], adult, article, bone marrow transplantation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37337Test
Transplant Infectious Disease
Click here for full text options
LibKey Link

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602Test
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

مصطلحات الفهرس: drug dose reduction, drug substitution, drug withdrawal, end stage renal disease/su [Surgery], end stage renal disease/th [Therapy], fever/co [Complication], gastroscopy, graft versus host reaction/dt [Drug Therapy], graft versus host reaction/pc [Prevention], Haemophilus parainfluenzae, hemolysis/di [Diagnosis], hemolysis/si [Side Effect], HLA matching, human, hypercholesterolemia, hypertension, hypotension/co [Complication], hypotension/dt [Drug Therapy], immunosuppressive treatment, intensive care, kidney biopsy, kidney cortex necrosis/di [Diagnosis], kidney pancreas transplantation, leg thrombosis/di [Diagnosis], leg thrombosis/dt [Drug Therapy], leukocyte count, low drug dose, male, medical history, middle aged, pancytopenia/si [Side Effect], paronychia/co [Complication], paronychia/dt [Drug Therapy], peritoneal dialysis, plasma exchange, Pseudomonas infection/co [Complication], Pseudomonas infection/dt [Drug Therapy], reflux esophagitis/di [Diagnosis], remission, review, sigmoidoscopy, thrombocyte count, thrombosis/dt [Drug Therapy], thrombosis/pc [Prevention], thrombosis prevention, thrombotic thrombocytopenic purpura/co [Complication], thrombotic thrombocytopenic purpura/di [Diagnosis], thrombotic thrombocytopenic purpura/dt [Drug Therapy], thrombotic thrombocytopenic purpura/th [Therapy], triacylglycerol lipase blood level, urinary tract infection/co [Complication], urinary tract infection/dt [Drug Therapy], vomiting/si [Side Effect], acetylsalicylic acid/dt [Drug Therapy], basiliximab/cb [Drug Combination], basiliximab/dt [Drug Therapy], beta2 glycoprotein 1/ec [Endogenous Compound], cardiolipin antibody/ec [Endogenous Compound], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], creatinine/ec [Endogenous Compound], eculizumab/ae [Adverse Drug Reaction], eculizumab/dt [Drug Therapy], eculizumab/iv [Intravenous Drug Administration], enoxaparin/dt [Drug Therapy], everolimus/dt [Drug Therapy], flucloxacillin/dt [Drug Therapy], flucloxacillin/iv [Intravenous Drug Administration], HLA antibody/ec [Endogenous Compound], inotropic agent/dt [Drug Therapy], leukocyte antigen/ec [Endogenous Compound], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], novel erythropoiesis stimulating protein/dt [Drug Therapy], phospholipid antibody/ec [Endogenous Compound], piperacillin plus tazobactam/dt [Drug Therapy], prednisolone/dt [Drug Therapy], tacrolimus/cb [Drug Combination], tacrolimus/dt [Drug Therapy], thymocyte antibody/dt [Drug Therapy], triacylglycerol lipase/ec [Endogenous Compound], warfarin/dt [Drug Therapy], catheter/am [Adverse Device Effect], human tissue, adult, anemia/di [Diagnosis], anemia/dt [Drug Therapy], antibody titer, bacterium identification, biochemical analysis, bone marrow biopsy, bone marrow suppression/di [Diagnosis], case report, catheter, creatinine blood level, deep vein thrombosis/di [Diagnosis], deep vein thrombosis/dt [Drug Therapy], diabetic retinopathy, diarrhea/co [Complication], diarrhea/si [Side Effect], Doppler flowmetry, drug dose increase, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39529Test
Nephrology
Click here for full text options
LibKey Link

مصطلحات الفهرس: kidney tubule disorder/co [Complication], long term survival, macrophage, male, neutrophil chemotaxis, peritubular capillaritis/dt [Drug Therapy], priority journal, proteinuria, single drug dose, azathioprine/cb [Drug Combination], cyclosporin/cb [Drug Combination], everolimus/cb [Drug Combination], HLA antibody/ec [Endogenous Compound], immunoglobulin/cb [Drug Combination], immunoglobulin/do [Drug Dose], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], methylprednisolone/cb [Drug Combination], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], mycophenolic acid/cb [Drug Combination], prednisolone/cb [Drug Combination], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], tacrolimus/cb [Drug Combination], peritubular capillaritis/co [Complication], prospective study, adult, antibody mediated rejection, article, capillaritis/co [Complication], capillaritis/dt [Drug Therapy], clinical article, drug megadose, estimated glomerular filtration rate, female, graft failure/co [Complication], graft survival, histology, human, human tissue, immunosuppressive treatment, inflammation, inflammatory cell, kidney biopsy, kidney transplantation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38610Test
Clinical Transplantation
Click here for full text options
LibKey Link

مصطلحات الفهرس: drug dose reduction, drug substitution, drug withdrawal, end stage renal disease/su [Surgery], end stage renal disease/th [Therapy], fever/co [Complication], gastroscopy, graft versus host reaction/dt [Drug Therapy], graft versus host reaction/pc [Prevention], Haemophilus parainfluenzae, hemolysis/di [Diagnosis], hemolysis/si [Side Effect], HLA matching, human, hypercholesterolemia, hypertension, hypotension/co [Complication], hypotension/dt [Drug Therapy], immunosuppressive treatment, intensive care, kidney biopsy, kidney cortex necrosis/di [Diagnosis], kidney pancreas transplantation, leg thrombosis/di [Diagnosis], leg thrombosis/dt [Drug Therapy], leukocyte count, low drug dose, male, medical history, middle aged, pancytopenia/si [Side Effect], paronychia/co [Complication], paronychia/dt [Drug Therapy], peritoneal dialysis, plasma exchange, Pseudomonas infection/co [Complication], Pseudomonas infection/dt [Drug Therapy], reflux esophagitis/di [Diagnosis], remission, review, sigmoidoscopy, thrombocyte count, thrombosis/dt [Drug Therapy], thrombosis/pc [Prevention], thrombosis prevention, thrombotic thrombocytopenic purpura/co [Complication], thrombotic thrombocytopenic purpura/di [Diagnosis], thrombotic thrombocytopenic purpura/dt [Drug Therapy], thrombotic thrombocytopenic purpura/th [Therapy], triacylglycerol lipase blood level, urinary tract infection/co [Complication], urinary tract infection/dt [Drug Therapy], vomiting/si [Side Effect], acetylsalicylic acid/dt [Drug Therapy], basiliximab/cb [Drug Combination], basiliximab/dt [Drug Therapy], beta2 glycoprotein 1/ec [Endogenous Compound], cardiolipin antibody/ec [Endogenous Compound], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], creatinine/ec [Endogenous Compound], eculizumab/ae [Adverse Drug Reaction], eculizumab/dt [Drug Therapy], eculizumab/iv [Intravenous Drug Administration], enoxaparin/dt [Drug Therapy], everolimus/dt [Drug Therapy], flucloxacillin/dt [Drug Therapy], flucloxacillin/iv [Intravenous Drug Administration], HLA antibody/ec [Endogenous Compound], inotropic agent/dt [Drug Therapy], leukocyte antigen/ec [Endogenous Compound], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], novel erythropoiesis stimulating protein/dt [Drug Therapy], phospholipid antibody/ec [Endogenous Compound], piperacillin plus tazobactam/dt [Drug Therapy], prednisolone/dt [Drug Therapy], tacrolimus/cb [Drug Combination], tacrolimus/dt [Drug Therapy], thymocyte antibody/dt [Drug Therapy], triacylglycerol lipase/ec [Endogenous Compound], warfarin/dt [Drug Therapy], catheter/am [Adverse Device Effect], human tissue, adult, anemia/di [Diagnosis], anemia/dt [Drug Therapy], antibody titer, bacterium identification, biochemical analysis, bone marrow biopsy, bone marrow suppression/di [Diagnosis], case report, catheter, creatinine blood level, deep vein thrombosis/di [Diagnosis], deep vein thrombosis/dt [Drug Therapy], diabetic retinopathy, diarrhea/co [Complication], diarrhea/si [Side Effect], Doppler flowmetry, drug dose increase, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39529Test
Nephrology
Click here for full text options
LibKey Link

مصطلحات الفهرس: kidney tubule disorder/co [Complication], long term survival, macrophage, male, neutrophil chemotaxis, peritubular capillaritis/dt [Drug Therapy], priority journal, proteinuria, single drug dose, azathioprine/cb [Drug Combination], cyclosporin/cb [Drug Combination], everolimus/cb [Drug Combination], HLA antibody/ec [Endogenous Compound], immunoglobulin/cb [Drug Combination], immunoglobulin/do [Drug Dose], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], methylprednisolone/cb [Drug Combination], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], mycophenolic acid/cb [Drug Combination], prednisolone/cb [Drug Combination], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], tacrolimus/cb [Drug Combination], peritubular capillaritis/co [Complication], prospective study, adult, antibody mediated rejection, article, capillaritis/co [Complication], capillaritis/dt [Drug Therapy], clinical article, drug megadose, estimated glomerular filtration rate, female, graft failure/co [Complication], graft survival, histology, human, human tissue, immunosuppressive treatment, inflammation, inflammatory cell, kidney biopsy, kidney transplantation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38610Test
Clinical Transplantation
Click here for full text options
LibKey Link

مصطلحات الفهرس: enteric coated tablet, fracture/si [Side Effect], gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunosuppressive treatment, incidence, kidney failure/si [Side Effect], leukopenia/si [Side Effect], lupus erythematosus nephritis/dt [Drug Therapy], maintenance therapy, Medline, ovary insufficiency/si [Side Effect], phase 1 clinical trial (topic), plasmapheresis, proliferative glomerulonephritis, proteinuria/si [Side Effect], randomized controlled trial (topic), relapse/pc [Prevention], relapse/si [Side Effect], remission, review, risk, side effect/si [Side Effect], single drug dose, systematic review, systemic lupus erythematosus, urine sediment, vomiting/si [Side Effect], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], corticosteroid/ct [Clinical Trial], corticosteroid/dt [Drug Therapy], creatinine/ec [Endogenous Compound], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporin/ae [Adverse Drug Reaction], cyclosporin/ct [Clinical Trial], cyclosporin/cm [Drug Comparison], cyclosporin/dt [Drug Therapy], cyclosporin A/ae [Adverse Drug Reaction], cyclosporin A/ct [Clinical Trial], cyclosporin A/cm [Drug Comparison], cyclosporin A/dt [Drug Therapy], heparin/cb [Drug Combination], heparin/dt [Drug Therapy], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/dt [Drug Therapy], methylprednisolone/ct [Clinical Trial], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], mycophenolic acid 2 morpholinoethyl ester/ae [Adverse Drug Reaction], mycophenolic acid 2 morpholinoethyl ester/ct [Clinical Trial], mycophenolic acid 2 morpholinoethyl ester/cm [Drug Comparison], mycophenolic acid 2 morpholinoethyl ester/dt [Drug Therapy], rituximab/ct [Clinical Trial], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], steroid/ct [Clinical Trial], steroid/ad [Drug Administration], steroid/cb [Drug Combination], steroid/cm [Drug Comparison], steroid/dt [Drug Therapy], steroid/iv [Intravenous Drug Administration], steroid/po [Oral Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], low drug dose, membranous glomerulonephritis, meta analysis, mortality, outcome assessment, alopecia/si [Side Effect], avascular necrosis/si [Side Effect], Cochrane Library, confidence interval, creatinine blood level, creatinine clearance, data extraction, diarrhea/si [Side Effect], disease classification, dosage schedule comparison, drug dose reduction, drug fatality/si [Side Effect], drug megadose, Embase, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/42603Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: kidney biopsy, kidney failure/su [Surgery], kidney failure/th [Therapy], adult, ANCA associated vasculitis/co [Complication], article, case report, drug efficacy, drug safety, drug withdrawal, female, glomerulonephritis/dt [Drug Therapy], glomerulonephritis/th [Therapy], glomerulus, hematuria, hemodialysis, human, immunosuppressive treatment, kidney allograft, kidney transplantation, plasmapheresis, postoperative complication/co [Complication], priority journal, recurrence risk, remission, renal replacement therapy, treatment duration, treatment outcome, basiliximab/cb [Drug Combination], creatinine/ec [Endogenous Compound], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/po [Oral Drug Administration], methylprednisolone/dt [Drug Therapy], mycophenolic acid/cb [Drug Combination], myeloperoxidase/ec [Endogenous Compound], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], tacrolimus/cb [Drug Combination], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28208Test
Click here for full text options
LibKey Link